Spritz-OM nasal therapy project to prevent ear infections receives $300,000 grant
A Western Australian research program which is developing a nasal probiotic therapy called Spritz-OM to prevent childhood ear infections has received a $300,000 grant to progress the project.
The therapy aims to use ‘friendly’ bacteria to guard the ear from otitis media (OM) and reduce overuse of antibiotics.
CUREator, a national biotechnology incubator, announced new top up funding will develop assays to enable phase one patient sample analysis and the generation of clinical proof-of-concept data for phase two.
The Spritz-OM research program is based at The Kids Research Institute Australia in Perth.
CUREator, which is funded by the Medical Research Future Fund and the CSIRO, supports Australian biomedical research and innovation development. Initial funding supported development of a master cell bank for GMP (Good Manufacturing Practice) manufacturing of Spritz-OM for future clinical studies.